Entera Bio Ltd. (NASDAQ:ENTX) is Knoll Capital Management LLC’s 3rd Largest Position

Knoll Capital Management LLC boosted its position in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 51.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 5,881,879 shares of the company’s stock after acquiring an additional 2,000,000 shares during the quarter. Entera Bio makes up about 8.0% of Knoll Capital Management LLC’s portfolio, making the stock its 3rd biggest position. Knoll Capital Management LLC owned 0.16% of Entera Bio worth $12,470,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Northern Trust Corp bought a new stake in shares of Entera Bio during the fourth quarter worth $450,000. 14.11% of the stock is owned by hedge funds and other institutional investors.

Entera Bio Price Performance

Shares of ENTX stock opened at $2.06 on Wednesday. The company’s 50-day simple moving average is $1.93 and its two-hundred day simple moving average is $2.04. Entera Bio Ltd. has a one year low of $1.41 and a one year high of $2.79. The company has a market capitalization of $93.63 million, a P/E ratio of -7.92 and a beta of 1.51.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. The firm had revenue of $0.04 million for the quarter. On average, research analysts expect that Entera Bio Ltd. will post -0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Entera Bio in a report on Tuesday, March 18th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.